Last reviewed · How we verify
Flupentixol melitracen tablets
Flupentixol is a typical antipsychotic that blocks dopamine D2 receptors, while melitracen is a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake, together providing antipsychotic and antidepressant effects.
Flupentixol is a typical antipsychotic that blocks dopamine D2 receptors, while melitracen is a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake, together providing antipsychotic and antidepressant effects. Used for Depression with psychotic features, Schizoaffective disorder.
At a glance
| Generic name | Flupentixol melitracen tablets |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | Typical antipsychotic + tricyclic antidepressant combination |
| Target | Dopamine D2 receptor (flupentixol); norepinephrine and serotonin transporters (melitracen) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination where flupentixol acts as a dopamine antagonist to reduce psychotic symptoms, and melitracen enhances monoamine neurotransmission by blocking reuptake of norepinephrine and serotonin to treat depression and anxiety. The combination is designed to address both psychotic and affective symptoms in conditions such as depression with psychotic features or schizoaffective disorder.
Approved indications
- Depression with psychotic features
- Schizoaffective disorder
Common side effects
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Sedation
- Anticholinergic effects (dry mouth, constipation, urinary retention)
- Orthostatic hypotension
- Weight gain
Key clinical trials
- Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (NA)
- Bioequivalence Study to Compare Two Formulations of Deanxit® (PHASE1)
- Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder (PHASE4)
- Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors (PHASE3)
- Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia (PHASE4)
- Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flupentixol melitracen tablets CI brief — competitive landscape report
- Flupentixol melitracen tablets updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI